Reduced intensity transplantation: Where are we now?

Hematology Journal

Volumn 5, Issue SUPPL. 3, 2004, Pages

  Mackinnon, Stephen ^a   Thomson, Kirsty ^a   Morris, Emma ^a   Kottaridis, Panagiotis D ^a   Peggs, Karls S ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; FLUDARABINE; IDARUBICIN; LYMPHOCYTE ANTIBODY; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; APLASIA; ARTICLE; BONE MARROW SUPPRESSION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE DEPLETION; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; NONHODGKIN LYMPHOMA; REMISSION; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; WHOLE BODY RADIATION;

ANTINEOPLASTIC AGENTS; BONE MARROW; CLINICAL TRIALS; COMBINED MODALITY THERAPY; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE DEPLETION; MYELODYSPLASTIC SYNDROMES; MYELOFIBROSIS; NEUTROPENIA; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 4043161288     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200419     Document Type: Article

References (19)

1. Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
2. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631-637.
3. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
4. Slavin, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
5. Nagler A, Slavin S, Varadi G, Naparstek E, Samuel S, Or R. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 2000; 25: 1021-1028.
6. Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 2000; 96: 2419-2425.
7. Peggs KS, Mackinnon S, Williams CD, D'Sa S, Thuraisundaram D, Kyriakou C. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. Biol Blood Marrow Transplant 2003; 9: 257-265.
8. Maloney DG, Molina AJ, Sahebi F, Stockeri-Goldstein KE, Sandmaier BM, Bensinger W. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447-3454.
9. Khouri IF, Saliba RM, Giralt SA, Lee MS, Okoroji GJ, Hagemeister FB. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001; 98: 3595-3599.
10. Morris E, Thompson K, Craddock C, Milligan D, Smith GM, Parker A. Long term follow-up of an alemtuzumab (Campath-1H) containing reduced intensity allogeneic transplant regimen for non-Hodgkin's lymphoma (NHL). Blood 2002; 100: 139a.
11. Faulkner RD, Craddock C, Byrne JL, Mahendra P, Haynes AP, Prentice HG. BEAM-Campath reduced intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity and survival in 65 patients. Blood 2003, epub ahead of print.
12. Spitzer TR. The expanding applications of non-myeloablative stem cell transplantation. Pediatr Transplant 2003; 7: (Suppl 3) 95-100.
13. Carella AM, Beltrami G, Carella Jr M, Corsetti MT, Scalzulli RP, Greco M. Immunosuppressive non-myeloablative allografting as salvage therapy in advanced Hodgkin's disease. Haematologica 2001; 86: 1121-1123.
14. Or R, Shapira MY, Resnick I, Amar A, Ackerstein A, Samuel S. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 2003; 101: 441-445.
15. Rondelli D, Barosi G, Bacigalupo A, Prchal JT, Popat U, Alessandrino EP. Non-myeloablative allogeneic HSCT in high risk patients with myelofibrosis. Blood 2003; 102: 199a.
16. Parker JF, Shafi T, Pagliuca A, Mijovic A, Devereux S, Potter M. Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br J Haematol 2002; 119: 144-154.
17. Kroger N, Bornhauser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol 2003; 82: 336-342.
18. Sayer HG, Kroger M, Beyer J, Kiehl M, Klein SA, Schaefer-Eckart K. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor. Bone Marrow Transplant 2003; 31: 1089-1095.
19. Finke J, Egger M, Grullich C, Potthoff K, Spyridonidis A, Waesch R. Myeloablative reduced conditioning with fludarabin, BCNU, melphalane (FBN) and stem cell transplantation from unrelated donors in elderly patients with active AML/MDS. Blood 2003; 102: 246a.